ProJect Pharmaceutics was granted a US patent on a novel liquid formulation of Bendamustine

ProJect Pharmaceutics was granted a US patent on a novel formulation which effectively stabilizes the anti-cancer drug Bendamustine and other N-mustard cancer drugs like Chlorambucil, Melphalan, Melflufen, etc. in liquid state at room temperature for up to 24 months. LIQUID PHARMACEUTICAL FORMULATION US-Patent No: 11,752,135 US-Application No: 17/042,795 Contact us for: – Details of the

Read More »

ProJect Pharmaceutics receives CIR application (Research Tax Credit) for the benefit of its French customers

ProJect Pharmaceutics is a contract research and development organization (CRO) specialized in formulation and process development for parenteral drug products. Expanding the offering of its service portfolio towards the French customer base, ProJect Pharmaceutics was engaged to apply at the French Ministère de L’Enseignement Supérieur, De La Recherche Et De L’Innovation for eligibility to join

Read More »

Meet ProJect Pharmaceutics at CPhI 2019

ProJect Pharmaceutics is glad to announce its participation as exhibitor at the upcoming CPhI trade fair, taking place in Frankfurt, Germany, November 5-7, 2019. We look forward to welcoming you at our booth #F23 in hall 9.2.

Read More »